Mr. Neil Weber reports

CARERX RECEIVES REGULATORY APPROVAL FOR RENEWAL OF ITS NORMAL COURSE ISSUER BID

The Toronto Stock Exchange has accepted CareRx Corp.'s notice to make a normal course issuer bid (NCIB) to repurchase outstanding common shares in the capital of the corporation.

"The renewal of our share repurchase program reflects the CareRx team's dedication to delivering robust cash generation and a disciplined capital allocation strategy," said Puneet Khanna, president and chief executive officer of CareRx. "Our repurchase program complements the company's quarterly dividend in returning capital to shareholders, while maintaining financial flexibility to support our continued growth and investments in the business."

The company reviews all elements of its capital allocation strategy on a continuing basis. The company remains committed to investing in organic and inorganic initiatives, including capital expenditures for capacity expansion and to support improved margins, and will also consider selective acquisition opportunities, which in the opinion of management and the board of directors will provide an attractive return on capital.

Normal course issuer bid

The TSX has approved the company's normal course issuer bid to purchase for cancellation up to 1.75 million common shares, representing approximately 2.75 per cent of the 63,429,589 common shares issued and outstanding as of Sept. 3, 2026.

It is expected that the NCIB will begin on Sept. 17, 2026, and will end on Sept. 16, 2027, or such earlier date as the NCIB is completed or is terminated in the discretion of the company. The average daily trading volume (ADTV) on the TSX for the six months ending Aug. 31, 2026, was 28,420 common shares. In accordance with TSX rules, the company may purchase up to 7,105 common shares on the TSX during any trading day, representing 25 per cent of the ADTV, subject to TSX rules permitting block purchases.

Purchases under the NCIB may be made through the facilities of the TSX, other designated exchanges and/or alternative Canadian trading systems, at prevailing market rates. Subject to regulatory approval, purchases under the NCIB may also be made by way of private agreements or share repurchase programs under issuer bid exemption orders issued by securities regulatory authorities. Any purchases made under an exemption order issued by a securities regulatory authority will generally be at a discount to the prevailing market price. The actual number of common shares to be purchased and the timing of any such purchases (if any) will be determined by the company, subject to the applicable rules of the TSX. Although the company intends to repurchase common shares under its NCIB, there can be no assurances that any such purchases will be completed. All common shares repurchased under the NCIB will be cancelled.

The company maintained a normal course issuer bid for the 12-month period commencing on Sept. 17, 2025, and ending on Sept. 16, 2026, under which the company sought and received approval from the TSX to purchase up to 1.5 million common shares. The company purchased 471,495 common shares under the previous NCIB at a weighted average purchase price of $3.56 per common share through the facilities of the TSX and alternative Canadian trading systems.

The company has established an automatic repurchase plan with its designated broker in order to facilitate purchases of common shares under the NCIB. Under the automatic repurchase plan, the company's designated broker may purchase common shares at times when the company ordinarily would not be active in the market due to its own internal trading blackout periods, insider trading rules or otherwise. Purchases made pursuant to the automatic repurchase plan, if any, will be made by the company's designated broker based upon the parameters prescribed by the TSX, applicable Canadian securities laws and the terms of the written agreement with the company. The automatic repurchase plan constitutes an automatic plan for purposes of applicable Canadian securities legislation and has been precleared by the TSX.

About CareRx Corp.

CareRx is Canada's leading provider of pharmacy services to seniors living and other congregate care communities (long-term care homes, retirement homes, assisted living facilities and group homes). The company is a national organization with a large network of pharmacy fulfilment centres strategically located across the country. This allows CareRx to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. The company uses best-in-class technology that automates the preparation and verification of multidose compliance packaging of medication, providing the highest levels of safety and adherence for individuals with complex medication regimens. CareRx takes an active role in working with its home operator partners to promote resident health, staff education, and medication system quality and efficiency.

We seek Safe Harbor.